The results newly showed that in terms of evaluating glucose variability and hypoglycemic episodes, using CGM metrics to complement HbA1c monitoring would be beneficial for patients treated with insulin and/or sulfonylureas, older patients, and patients with CKD (Supplementary Table 4 (22)). This evidence concerns the gene INS and chronic kidney disease.